EGFR and multiple sclerosis: We discovered that ruxolitinib at clinically relevant free drug concentrations synergized with the multiple sclerosis drug MMF to kill a wide variety of solid tumor cell types, particularly breast and brain tumor cells, including those cells expressing mutated active RAS or ERBB1 proteins, or lacking the tumor suppressor PTEN.